HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech

Novo Nordisk has found the latest buyer for one of its orphaned cell therapies.

By FierceBiotech · May 14, 2026 · via FierceBiotech
Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
DealsEndpoints News ↗
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill …
May 12, 2026
BMS Bets on China’s Speed in $15B Hengrui R&D Pact
DealsBriefing
BMS Bets on China’s Speed in $15B Hengrui R&D Pact
Bristol Myers Squibb will pay $600M upfront in a $15.2B collaboration with Hengrui, aiming to leverage China’s…
May 12, 2026
GSK cuts deal with Sino to broaden reach of hepatitis B drug
DealsBioPharma Dive ↗
GSK cuts deal with Sino to broaden reach of hepatitis B drug
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and c…
May 11, 2026